ベータ (((2) - アドレナゲン受容体の過剰発現は,大動脈狭窄後の心不全の発症を悪化させる
X J Du1, D J Autelitano, R J Dilley
1Baker Medical Research Institute, Melbourne, Australia. xiaojun.du@baker.edu.au
Circulation
|January 5, 2000
まとめ
ベータ-2アドレネルゲン受容体の活性が上昇すると,圧力過負荷後の心不全が悪化する. マウスにおけるこれらの受容体の過剰発現は,死亡率の増加と心臓機能不全につながった.
科学分野:
- 心臓病学 心臓病学
- 分子生物学は分子生物学である.
- 生理学 生理学とは
背景:
- ベータアドレナジックシグナル伝達は心臓機能に不可欠ですが,心不全におけるその役割は完全に理解されていません.
- このシグナル伝達経路のダウンレギュレーションは,心不全で観察され,その重要性についての調査を促しています.
研究 の 目的:
- 心不全 (HF) の進行におけるベータアドレナジック機能障害の役割を調査する.
- 圧力過負荷条件下におけるベータ-2 アドレナリゲン受容体 (AR) 活性の増加が心臓機能に与える影響を決定する.
主な方法:
- 大動脈狭窄症 (AS) は,心筋ベータ2) -ARs.s.を過剰発現した野生型 (WT) とトランス遺伝子型 (TG) のマウスで誘発された.
- ヘモダイナミックパラメータ,心筋縮,遺伝子発現 (ANP mRNA),および生存率は,誘導後9週間で評価されました.
- 心筋線維症と左心室 (LV) 機能不全を評価するために,組織学的分析が行われました.
主要な成果:
- ASを有するTGマウスは,WTマウスと比較して,シストリック圧力とLV増幅の同様の増加を示した.
- しかし,TGマウスは,早死,心不全,膜流出,心房血栓症の発生率が著しく高かった.
- 広範な焦点線維症とより重度のLV機能障害は,ASのWTマウスと比較して,TGマウスで観察されました.
結論:
- 心臓のβ-ARsの過剰発現は,圧力の過剰負荷に伴う心臓の機能的悪化を悪化させる.
- ベータ・アドレナジックの活性が上昇すると,心不全モデルにおける有害な結果に寄与する.
関連する概念動画
01:26Adrenergic Receptors: β Subtype
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
01:17Antihypertensive Drugs: Action of β1 Blockers
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...